FIELD: chemistry.
SUBSTANCE: in formula (1) compound, cysteinprotease is cathepsin K, cathepsin S, cathepsin L or cathepsin B. In formula (I) 
R is 
, AA1 is a bond, AA2 is a bond, R7 and R8 each independently represents hydrogen, C1-8 alkyl, CycA or C1-8 alkyl, substituted CycA, R9 is hydrogen, values of the rest of the radicals are given in the formula of invention. The invention also relates to a pharmaceutical composition, containing a formula (I) compound as an active ingredient, to a cysteinprotease inhibitor, method of inhibiting cysteinprotease, use of formula (I) compound in obtaining cysteinprotease inhibitor.
EFFECT: compound has inhibitory activity towards cysteinprotease.
10 cl, 16 tbl, 8 dwg, 224 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYTOSKELETON-ACTIVE COMPOUNDS, COMPOSITIONS AND USE | 2006 |
|
RU2407745C2 |
| NOVEL CYCLOPENTANE DERIVATIVES | 2010 |
|
RU2572555C2 |
| HEXAHYDRONAPHTHALENE ESTER DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1994 |
|
RU2114101C1 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 2017 |
|
RU2747318C2 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 2022 |
|
RU2803084C1 |
| AMINOPYRIDINE DERIVATIVES AND APPLICATION THEREOF AS SELECTIVE ALK-2 INHIBITORS | 2017 |
|
RU2777979C2 |
| CATHEPSIN CYSTEINE PROTEASE INHIBITORS | 2014 |
|
RU2692799C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
| 1-CYANOCYCLOPROPYL DERIVATIVES AS CATHEPSIN K INHIBITORS | 2008 |
|
RU2470023C2 |
